Literature DB >> 17416214

High-performance liquid chromatographic method with UV photodiode-array, fluorescence and mass spectrometric detection for simultaneous determination of galantamine and its phase I metabolites in biological samples.

Jana Maláková1, Milan Nobilis, Zbynek Svoboda, Miroslav Lísa, Michal Holcapek, Jaroslav Kvetina, Jirí Klimes, Vladimír Palicka.   

Abstract

Galantamine, an alkaloid isolated from the bulbs and flowers of Caucasian snowdrop (Galanthus woronowii, Amaryllidaceae) and related species, is employed in human medicine for the treatment of various neuromuscular and neurodegenerative diseases. After the administration, the products of oxidative biotransformation (O-desmethyl-galantamine, N-desmethyl-galantamine, galantamine-N-oxide) and chiral conversion (epigalantamine) are formed in various concentrations from parent compound. For the identification and determination of galantamine and its phase I metabolites in blood plasma and tissues, a new bioanalytical method based on a reversed-phase high-performance liquid chromatography with UV photodiode-array, fluorescence and mass spectrometric detection was developed, validated and applied to pharmacokinetic and biotransformation studies. Sample preparation included a homogenization of the rat tissues (liver, brain, hypophysis) in a phosphate buffer 0.05 mol/L pH 7.4. Plasma samples and tissue homogenates were purified using a mixed-mode solid-phase extraction (Waters Oasis MCX cartridges). Galantamine, its above-mentioned metabolites and the internal standard codeine were separated on a Discovery HS F5 column (Supelco, 150 mmx4.6 mm I.D., 5 microm) at flow rate of 1 mL/min using a linear gradient elution. UV photodiode-array and mass spectrometric detection were employed for the identification of individual galantamine metabolites in various biomatrices, the fluorescence detection (lambdaexcit=280 nm/lambdaemiss=310 nm) was chosen for the quantification of galantamine and its metabolites. The developed method was applicable in liver tissue in the range from 0.50 to 63.47 nmol/g of galantamine, from 0.32 to 41.42 nmol/g of O-desmethyl-galantamine, from 0.54 to 69.40 nmol/g of N-desmethyl-galantamine and from 0.70 to 89.03 nmol/g of epigalantamine. Limit of detection was found to be 0.04 nmol/g for galantamine, 0.19 nmol/g for O-desmethyl-galantamine, and 0.07 nmol/g for N-desmethyl-galantamine and epigalantamine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17416214     DOI: 10.1016/j.jchromb.2007.03.025

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application.

Authors:  Carina Wattmo; Erik Jedenius; Kaj Blennow; Asa K Wallin
Journal:  Alzheimers Res Ther       Date:  2013-01-03       Impact factor: 6.982

2.  Determination of galantamine hydrobromide in bulk drug and pharmaceutical dosage form by spectrofluorimetry.

Authors:  Amit V Patel; Vishal J Patel; Avani V Patel; Jayant B Dave; Chhaganbhai N Patel
Journal:  J Pharm Bioallied Sci       Date:  2013-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.